Review

u1144 optimisation thérapeutique en neuropharmacologie opten (Inserm Transfert)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Inserm Transfert u1144 optimisation thérapeutique en neuropharmacologie opten
U1144 Optimisation Thérapeutique En Neuropharmacologie Opten, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optimisations/1140+en+france+h%C3%A9mostase+innovation+inserm+th%C3%A9rapeutique+umrs/pm41899390-0-2-1
Average 86 stars, based on 1 article reviews

u1144 optimisation thérapeutique en neuropharmacologie opten - by Bioz Stars, 2026-09

86/100 stars

Images

other:

Article Title: The influence of CHRNA5 and D398N missense variation on social and emotional behaviors in rodents and humans.
Article Snippet: 3UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Inserm, Université Paris Cité, 4 avenue de l’observatoire, Paris 75006, France.

Article Title: Cost-utility of point-of-care viscoelastic hemostatic assays in the management of bleeding during cardiac surgery: a single-blinded prospective multicenter stepped wedge cluster randomized trial in French context.
Article Snippet: INSERM UMR-S1140 “Innovations Thérapeutiques en Hémostase”, Université Paris Cité, (75004) Paris, France. (13) Service d’Anesthésie Réanimation - CHU La Timone – APHM, UR 4264 - Centre Européen de Recherche en Imagerie Médicale - Aix-Marseille Université (13000) Marseille.

Article Title: Retraction notice to "Reconstruction of a septic femoral triangle fistula with a pedicled DIEP flap: A case report and mini-review" (Reconstruction d'une fistule septique du triangle fémoral par un lambeau pédiculé de DIEP : cas clinique et mini-revue de la littérature) [Ann Chir Plast Esthet 2024;69(3):233-38].
Article Snippet: Vascularized Composite Allotransplantation Laboratory, Massachusetts General Hospital, Harvard Medical chool, 50 Blossom Street, Boston, MA, United States Shriners Children’s Boston, Harvard Medical School, Boston, MA, United States Department of Plastic, Reconstructive and Aesthetic Surgery, Rennes University Hospital Center, Rennes, rance Department of Vascular Surgery, hôpital européen Georges-Pompidou, Assistance publique—Hôpitaux de aris, Paris, France Inserm UMRS 1140 Innovation thérapeutique en hémostase, université de Paris, Paris, France

Article Title: Cost-utility of point-of-care viscoelastic hemostatic assays in the management of bleeding during cardiac surgery: a single-blinded prospective multicenter stepped wedge cluster randomized trial in French context.
Article Snippet: Jo ur na l P re -p ro of Page of 41 22 • Department of Anesthesiology and Intensive Care, Hôpital Européen Georges Pompidou, AP-HP (20 rue Leblanc) Paris, (75015) France, INSERM UMR-S1140 “Innovations Thérapeutiques en Hémostase”, Université Paris Cité, Paris.

Article Title: Retraction notice to "Reconstruction of a septic femoral triangle fistula with a pedicled DIEP flap: A case report and mini-review" (Reconstruction d'une fistule septique du triangle fémoral par un lambeau pédiculé de DIEP : cas clinique et mini-revue de la littérature) [Ann Chir Plast Esthet 2024;69(3):233-38].
Article Snippet: El Batti d,e, A.G. Lellouch a,b Vascularized Composite Allotransplantation Laboratory, Massachusetts General Hospital, Harvard Medical chool, 50 Blossom Street, Boston, MA, United States Shriners Children’s Boston, Harvard Medical School, Boston, MA, United States Department of Plastic, Reconstructive and Aesthetic Surgery, Rennes University Hospital Center, Rennes, rance Department of Vascular Surgery, hôpital européen Georges-Pompidou, Assistance publique—Hôpitaux de aris, Paris, France Inserm UMRS 1140 Innovation thérapeutique en hémostase, université de Paris, Paris, France nglish version his article has been retracted: please see Elsevier Policy on rticle Withdrawal (https://www.elsevier.com/about/ olicies-and-standards/article-withdrawal).

Enzyme-linked Immunosorbent Assay:

Article Title: Correction: Ficany et al. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. J. Clin. Med. 2025, 14 , 7724.
Article Snippet: .. 2025, 14, 7724 Anthony Ficany 1, Marta Del Alamo 2, Carmelo Bernabeu 3 , Claire L. Shovlin 4,5 and Elisa Rossi 1,* 1 INSERM, U1144 Optimisation Thérapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Université Paris-Cité, 75006 Paris, France; anthony.ficany@u-paris.fr 2 ECRIN—European Clinical Research Infrastructure Network, 75014 Paris, France; marta.delalamo@ecrin.org 3 Department of Biomedicine, Centro de Investigaciones Biológicas “Margarita Salas”, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain; bernabeu.c@cib.csic.es 4 National Heart and Lung Institute, Imperial College London, London W12 0NN, UK; c.shovlin@imperial.ac.uk 5 Specialist Medicine, Imperial College Healthcare NHS Trust, London W12 0HS, UK * Correspondence: elisa.rossi@u-paris.fr In the original publication [1] a sentence could have led to a misunderstanding or misinterpretation; therefore, we chose to correct it in Section 2.4. ..

Article Title: Correction: Ficany et al. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. J. Clin. Med. 2025, 14 , 7724.
Article Snippet: .. 1 INSERM, U1144 Optimisation Thérapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Université Paris-Cité, 75006 Paris, France; anthony.ficany@u-paris.fr 2 ECRIN—European Clinical Research Infrastructure Network, 75014 Paris, France; marta.delalamo@ecrin.org 3 Department of Biomedicine, Centro de Investigaciones Biológicas “Margarita Salas”, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain; bernabeu.c@cib.csic.es 4 National Heart and Lung Institute, Imperial College London, London W12 0NN, UK; c.shovlin@imperial.ac.uk 5 Specialist Medicine, Imperial College Healthcare NHS Trust, London W12 0HS, UK * Correspondence: elisa.rossi@u-paris.fr ..

Similar Products

Image Search Results

$( a ) Schematics depicting ( left ) the Am-S genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).$

Journal: bioRxiv

Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

doi: 10.64898/2026.06.01.729406

Figure Lengend Snippet: ( a ) Schematics depicting ( left ) the Am-S genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).

Article Snippet: The E. coli codon optimised AmEnc-SpyCatcher (Am-S) sequence ( Table S2 ) was synthesised by Twist Bioscience into the pET-24(+) expression vector and transformed into E. coli BL21(DE3) competent cells (New England Biolabs).

Techniques: Construct, Purification, SDS Page, Clear Native PAGE, Cryo-EM Sample Prep, Solubility, Isolation, Centrifugation

( a ) Schematic of peptide antigens with an N-terminal SpyTag (orange) linked via a flexible (GS)n spacer (black) to peptide antigens derived from pTau (S-pTau; green) or Aβ (S-Aβ; purple). ( b ) Conceptual illustration of unconjugated and conjugated Am-S, including the bare nanoscaffold (Am-S), monovalent nanocage formats bearing S-pTau (Am-S-pTau) or S-Aβ (Am-S-Aβ), and a multivalent “mosaic” nanocage bearing both antigens. ( c ) PAGE assessment of SpyTag/SpyCatcher-mediated conjugation, with ( left ) SDS-PAGE showing covalent coupling of antigen(s) to the Am-S subunit, and ( right ) non-denaturing native PAGE indicating antigen (co-)display on the assembled Am-S nanocage. ( d ) DLS characterisation of hydrodynamic diameter and dispersity of the (co-)conjugated nanocages. ( e ) Negatively stained TEM images of Am-S (orange), Am-S-pTau (green), Am-S-Aβ (purple), and mosaic (blue) nanocage formats; Scale bars = 200 nm.

Journal: bioRxiv

Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

doi: 10.64898/2026.06.01.729406

Figure Lengend Snippet: ( a ) Schematic of peptide antigens with an N-terminal SpyTag (orange) linked via a flexible (GS)n spacer (black) to peptide antigens derived from pTau (S-pTau; green) or Aβ (S-Aβ; purple). ( b ) Conceptual illustration of unconjugated and conjugated Am-S, including the bare nanoscaffold (Am-S), monovalent nanocage formats bearing S-pTau (Am-S-pTau) or S-Aβ (Am-S-Aβ), and a multivalent “mosaic” nanocage bearing both antigens. ( c ) PAGE assessment of SpyTag/SpyCatcher-mediated conjugation, with ( left ) SDS-PAGE showing covalent coupling of antigen(s) to the Am-S subunit, and ( right ) non-denaturing native PAGE indicating antigen (co-)display on the assembled Am-S nanocage. ( d ) DLS characterisation of hydrodynamic diameter and dispersity of the (co-)conjugated nanocages. ( e ) Negatively stained TEM images of Am-S (orange), Am-S-pTau (green), Am-S-Aβ (purple), and mosaic (blue) nanocage formats; Scale bars = 200 nm.

Techniques: Derivative Assay, Conjugation Assay, SDS Page, Clear Native PAGE, Staining

( a ) Immunisation schedule for C57BL/6J mice ( n = 4 per group) with end-point sera collection. ( b ) ELISA measurement of anti-pTau total IgG levels in terminal sera from mice receiving Am-S-pTau and controls. ( c ) Body-weight change of mice over time-course in (b), expressed as normalised area under the curve (AUC). ( Right panel ) AddaVax™ and Alhydrogel®. ( d ) Immunisation and sera collection schedule for mice receiving Am-S-pTau formulated with ADV or ALH ( n = 4 per group). ( e ) Anti-pTau IgG titres in sera over time. Black arrows indicate immunization days. ( f ) Body-weight change over time in (e). Data are mean ± SD. ****P < 0.0001; ns, non-significant (> 0.05). Statistical analyses: one-way ANOVA with Tukey’s multiple comparisons for (b,c,f); two-way mixed-effects ANOVA with time and adjuvant as factors for (e).

Journal: bioRxiv

Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

doi: 10.64898/2026.06.01.729406

Figure Lengend Snippet: ( a ) Immunisation schedule for C57BL/6J mice ( n = 4 per group) with end-point sera collection. ( b ) ELISA measurement of anti-pTau total IgG levels in terminal sera from mice receiving Am-S-pTau and controls. ( c ) Body-weight change of mice over time-course in (b), expressed as normalised area under the curve (AUC). ( Right panel ) AddaVax™ and Alhydrogel®. ( d ) Immunisation and sera collection schedule for mice receiving Am-S-pTau formulated with ADV or ALH ( n = 4 per group). ( e ) Anti-pTau IgG titres in sera over time. Black arrows indicate immunization days. ( f ) Body-weight change over time in (e). Data are mean ± SD. ****P < 0.0001; ns, non-significant (> 0.05). Statistical analyses: one-way ANOVA with Tukey’s multiple comparisons for (b,c,f); two-way mixed-effects ANOVA with time and adjuvant as factors for (e).

Techniques: Enzyme-linked Immunosorbent Assay, Adjuvant

Representative immunohistochemical staining of (Left panel) amygdala sections from tauopathy TAU58/2 mice with the corresponding region from wild-type mice controls ( n = 1); and (Right panel) hippocampal sections from amyloidogenic APP/PS1 mice with the corresponding region from wild-type controls ( n = 1). As indicated, ex vivo brain sections were incubated with sera from C57BL/6J mice immunised with single-targeting nanovaccines (Am-S-pTau or Am-S-Aβ), or dual-targeting mosaic or cocktail formulations. Positive control antibodies were included: PHF-1 that recognizes pTau (pSer396/404); or 6E10 that binds Aβ (residues 1-16/17). Pathology-bound IgG was detected using Alexa Fluor 488 (green) and Alexa Fluor 568 or 647 (orange). Cell nuclei were counterstained with DAPI (blue). Scale bars = 200 µm (TAU58/2); or 500 µm (APP/PS1) and 200 µm (zoomed-in region, APP-PS1).

Journal: bioRxiv

Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

doi: 10.64898/2026.06.01.729406

Figure Lengend Snippet: Representative immunohistochemical staining of (Left panel) amygdala sections from tauopathy TAU58/2 mice with the corresponding region from wild-type mice controls ( n = 1); and (Right panel) hippocampal sections from amyloidogenic APP/PS1 mice with the corresponding region from wild-type controls ( n = 1). As indicated, ex vivo brain sections were incubated with sera from C57BL/6J mice immunised with single-targeting nanovaccines (Am-S-pTau or Am-S-Aβ), or dual-targeting mosaic or cocktail formulations. Positive control antibodies were included: PHF-1 that recognizes pTau (pSer396/404); or 6E10 that binds Aβ (residues 1-16/17). Pathology-bound IgG was detected using Alexa Fluor 488 (green) and Alexa Fluor 568 or 647 (orange). Cell nuclei were counterstained with DAPI (blue). Scale bars = 200 µm (TAU58/2); or 500 µm (APP/PS1) and 200 µm (zoomed-in region, APP-PS1).

Techniques: Immunohistochemical staining, Staining, Ex Vivo, Incubation, Positive Control

Review

Structured Review

Images

Related Articles

other:

Enzyme-linked Immunosorbent Assay:

Similar Products

Image Search Results